Effect of Low-Dose Remimazolam on Etomidate-Induced Myoclonus

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300079274

Enrollment

Unknown

Registered

2023-12-29

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group(Group R):Low-dose remimazolam was injected intravenously before etomidate in the remimazolam group

Control group(Group C):The same volume of normal saline was given intravenously

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients undergoing elective neurointerventional procedures; 2) Patients of both sexes, Age =18 years old, ASA(American Society of Anesthesiologists) ?-?; 3) All patients are informed and signed the informed consent for surgery and anesthesia.

Exclusion criteria

Exclusion criteria: 1) Patients with epilepsy or mental disorders; 2) Patients with myasthenia gravis; 3) Patients having a history of allergy to etomidate and benzodiazepines; 4) Patients taking sedative and analgesic drugs on the day of surgery; 5) Patients with expected difficult airway; 6) Patients having a history of alcoholism or addiction to opioids or benzodiazepines. 7) Patients with adrenal cortex dysfunction; 8) Patients having severe liver and kidney dysfunction; Heart failure;

Design outcomes

Primary

Measure	Time frame
the incidence of myoclonus;the severity of myoclonus;	—

Secondary

Measure	Time frame
Injection pain score at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Blood pressure at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Respiratory rate at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;BIS values at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Pulse oxygen saturation(SpO2) at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Sedation scores at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;	—

Measure

Time frame

Injection pain score at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Blood pressure at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Respiratory rate at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;BIS values at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Pulse oxygen saturation(SpO2) at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;Sedation scores at baseline (t0), before study drugs administration (t1), 90s after administration (t2), 1min (t3) and 3min (t4) after etomidate administration;

—

Countries

China

Contacts

Public ContactXing Na

The First Affiliated Hospital of Zhengzhou University

16427485@qq.com+86 139 4909 5172

Outcome results